Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has been invited to present at UCLA's exclusive symposium on Anti-Obesity Treatments: Challenges and Emerging Solutions. The company will showcase EL-22, their groundbreaking engineered probiotic designed to preserve muscle mass during weight loss treatments.
The symposium, organized by UCLA Metabolism Theme at David Geffen School of Medicine, brings together leading obesity clinicians, researchers, drug developers, and investors. EL-22 addresses a critical challenge in current obesity treatments, particularly with GLP-1 receptor agonists, where 30-50% of body weight lost is lean muscle mass—a side effect without approved treatments.
The presentation is scheduled for February 7th at 11:30 am PT, where Northstrive Biosciences aims to connect with key opinion leaders, investors, and established pharma companies in the obesity space.
Northstrive Biosciences, una sussidiaria di PMGC Holdings (NASDAQ: ELAB), è stata invitata a presentare al simposio esclusivo dell'UCLA sui Trattamenti Anti-Obesità: Sfide e Soluzioni Emergenti. L'azienda presenterà EL-22, il loro innovativo probiotico ingegnerizzato progettato per preservare la massa muscolare durante i trattamenti per la perdita di peso.
Il simposio, organizzato dal Tema Metabolismo dell'UCLA presso la David Geffen School of Medicine, riunisce i principali clinici, ricercatori, sviluppatori di farmaci e investitori nel campo dell'obesità. EL-22 affronta una sfida critica nei trattamenti contro l'obesità attuali, in particolare con gli agonisti del recettore GLP-1, dove il 30-50% del peso corporeo perso è massa muscolare magra—un effetto collaterale per il quale non esistono trattamenti approvati.
La presentazione è programmata per il 7 febbraio alle 11:30 ora del Pacifico, dove Northstrive Biosciences mira a connettersi con leader di opinione chiave, investitori e aziende farmaceutiche consolidate nel settore dell'obesità.
Northstrive Biosciences, una subsidiaria de PMGC Holdings (NASDAQ: ELAB), ha sido invitada a presentar en el simposio exclusivo de UCLA sobre Tratamientos Antiobesidad: Desafíos y Soluciones Emergentes. La compañía presentará EL-22, su probiótico innovador diseñado para preservar la masa muscular durante los tratamientos de pérdida de peso.
El simposio, organizado por el Tema de Metabolismo de UCLA en la David Geffen School of Medicine, reúne a destacados clínicos de la obesidad, investigadores, desarrolladores de fármacos e inversores. EL-22 aborda un desafío crítico en los tratamientos actuales contra la obesidad, particularmente con los agonistas del receptor GLP-1, donde el 30-50% del peso corporal perdido es masa muscular magra—un efecto secundario sin tratamientos aprobados.
La presentación está programada para el 7 de febrero a las 11:30 am PT, donde Northstrive Biosciences busca conectar con líderes de opinión clave, inversores y empresas farmacéuticas consolidadas en el campo de la obesidad.
Northstrive Biosciences, PMGC Holdings의 자회사 (NASDAQ: ELAB), UCLA의 비만 치료: 도전과.emerging solutions라는 독점 심포지엄에 초청되었습니다. 이 회사는 체중 감소 치료 중 근육량을 보존하기 위해 설계된 획기적인 엔지니어링 프로바이오틱인 EL-22를 선보일 예정입니다.
UCLA David Geffen 의대 대사 주제에 의해 조직된 이 심포지엄은 비만 분야의 주요 임상 의사, 연구원, 약품 개발자, 투자자들을 모은 것입니다. EL-22는 현재 비만 치료에서 GLP-1 수용체 작용제와 관련하여 여전히 도전과제를 해결하는 중요한 해결책을 제시합니다. 이 치료에서 체중이 30-50% 감소하면 탄력 있는 근육량이 떨어지는 부작용이 발생하는데, 이는 승인된 치료법이 없습니다.
프레젠테이션은 2월 7일 오전 11:30(태평양 표준시)로 예정되어 있으며, Northstrive Biosciences는 비만 분야의 주요 의견 지도자, 투자자 및 기존 제약 회사와 연결할 계획입니다.
Northstrive Biosciences, une filiale de PMGC Holdings (NASDAQ: ELAB), a été invitée à présenter lors du symposium exclusif de l'UCLA sur Traitements contre l'obésité : Défis et Solutions Émergentes. L'entreprise présentera EL-22, leur probiotique révolutionnaire conçu pour préserver la masse musculaire pendant les traitements de perte de poids.
Le symposium, organisé par le thème Métabolisme de l'UCLA à la David Geffen School of Medicine, réunit des cliniciens, chercheurs, développeurs de médicaments et investisseurs de premier plan dans le domaine de l'obésité. EL-22 répond à un défi critique dans les traitements actuels contre l'obésité, notamment avec les agonistes du récepteur GLP-1, où 30-50 % du poids corporel perdu est de la masse musculaire maigre—un effet secondaire sans traitements approuvés.
La présentation est prévue pour le 7 février à 11h30 PT, où Northstrive Biosciences espère se connecter avec des leaders d'opinion clés, des investisseurs et des entreprises pharmaceutiques établies dans le domaine de l'obésité.
Northstrive Biosciences, eine Tochtergesellschaft von PMGC Holdings (NASDAQ: ELAB), wurde eingeladen, beim exklusiven Symposium der UCLA über Anti-Adipositas-Behandlungen: Herausforderungen und aufkommende Lösungen zu präsentieren. Das Unternehmen wird EL-22 vorstellen, ein bahnbrechendes engineered Probiotikum, das entwickelt wurde, um Muskelmasse während der Gewichtsverlustbehandlungen zu erhalten.
Das Symposium, organisiert vom UCLA Metabolism Theme an der David Geffen School of Medicine, versammelt führende Adipositas-Kliniker, Forscher, Arzneimittelentwickler und Investoren. EL-22 geht eine kritische Herausforderung in den aktuellen Adipositas-Behandlungen an, insbesondere mit GLP-1-Rezeptor-Agonisten, wo 30-50% des verlorenen Körpergewichts aus fettfreier Muskelmasse besteht—ein Nebenwirkung ohne genehmigte Behandlungen.
Die Präsentation ist für den 7. Februar um 11:30 Uhr PT angesetzt, bei der Northstrive Biosciences beabsichtigt, sich mit wichtigen Meinungsführern, Investoren und etablierten Pharmaunternehmen im Bereich der Adipositas zu vernetzen.
- None.
- None.
Northstrive Biosciences Inc. was invited to present EL-22, a novel myostatin asset aimed at preserving muscle while on weight loss treatments, at the UCLA Obesity Symposium called Anti-Obesity Treatments: Challenges and Emerging Solutions, organized by UCLA Metabolism Theme. This is an invite only event that brings together industry leading voices in the obesity space.
NEWPORT BEACH, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB), today announced that Northstrive Biosciences Inc. (“Northstrive Biosciences”) has been invited to present at the upcoming symposium called Anti-Obesity Treatments: Challenges and Emerging Solutions organized by UCLA Metabolism Theme. UCLA Metabolism Theme is an initiative at UCLA David Geffen School of Medicine aiming to facilitate campus wide interdisciplinary research in the field of metabolism involving basic, clinical, and industry collaborations
This timely symposium brings together industry leading, obesity focused clinicians, researchers, drug developers and investors to address the challenges brought up by weight loss treatments. Northstrive Biosciences has been invited to present lead asset EL-22, which leverages a first-in-class engineered probiotic approach for preserving muscle while on weight loss treatments.
“The rise of anti-obesity medications has put the spotlight on the challenges being faced, particularly the management of muscle and bone loss associated with GLP-1 receptor agonists,” stated Orian Shirihai, MD, PhD, the Director of UCLA’s Metabolism Theme. “We organized this event to gather obesity’s leading opinion leaders to review the gaps and highlight the emerging solutions. I am pleased that Northstrive Biosciences has accepted our invitation to give a talk at the event.”
Northstrive Biosciences will showcase EL-22, a first-in-class engineered probiotic designed to preserve muscle mass in patients undergoing weight-loss treatments, including GLP-1 receptor agonists. This groundbreaking therapeutic addresses a critical gap in current obesity treatments, where up to
[1][2] Studies show that approximately 30
“We are looking forward to presenting EL-22 as a next-generation solution to the common muscle wasting side effect,” said Deniel Mero, Co-founder of Northstrive Biosciences. “We’re honored to contribute a lecture and are looking to connect with key opinion leaders, investors and established pharma companies in the obesity space.”
Northstrive Biosciences’ management is scheduled to present on Friday, February 7th at 11:30 am PT.
About Northstrive Biosciences
Northstrive Biosciences Inc., a PMGC Holdings company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Its lead asset, EL-22, is leveraging an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC Holdings’ filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
IR@pmgcholdings.com
1 Reference: Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinol Metab (Seoul). 2019 Sep;34(3):247-262. doi: 10.3803/EnM.2019.34.3.247
2 Reference: Beavers KM, Cortes TM, Foy CM, et al. GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials. Obesity (Silver Spring). 2024; 1-13. https://doi.org/10.1002/oby.24172
FAQ
What is EL-22 and how does it address muscle loss in weight loss treatments?
When will Northstrive Biosciences (ELAB) present at the UCLA Obesity Symposium?
What percentage of weight loss from GLP-1 treatments is muscle mass?
Why was Northstrive Biosciences (ELAB) chosen for the UCLA Obesity Symposium?
What is the purpose of the UCLA Anti-Obesity Treatments symposium?
